Treatment with Hypomethylating Agents (HMA) View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2018-06-06

AUTHORS

Ulrich Germing , Pierre Fenaux

ABSTRACT

In 1993 Silverman and coworkers [1] reported on a phase 2 trial on 43 patients with higher-risk MDS (medullary blast count >10%) using 75 mg/m2 5-Azacytidine (5-Aza) for 7 days every 28 days for 6 cycles. Forty-nine percent of the patients responded, with 12% CR (CR and PR 37%, and 5% improved hematologically without achieving CR or PR), and 51% were nonresponders. This report was the first to show that 5-Aza can result in remission in a reasonable proportion of the patients, and results were very closely reproduced in phase 2 and 3 trials [2–18]. The drug was regarded as differentiating agent, and the authors speculated if 5-Aza was the first drug with benefit for older MDS patients. In 1997 Wijermans et al. [19] published promising phase 2 data on decitabine in high-risk MDS with similar results and subsequently worked on different schedules and on cytogenetic responses as well. Having in mind the very poor prognosis of older high-risk MDS patients after induction chemotherapy [20, 21], the efficacy of HMA appears to be an attractive alternative. More... »

PAGES

131-139

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-319-76879-3_10

DOI

http://dx.doi.org/10.1007/978-3-319-76879-3_10

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1104407947


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Germing", 
        "givenName": "Ulrich", 
        "id": "sg:person.01362464041.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital St Louis (Assistance Publique \u2013H\u00f4pitaux de Paris) and Paris 7 University, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.413328.f", 
          "name": [
            "H\u00f4pital St Louis (Assistance Publique \u2013H\u00f4pitaux de Paris) and Paris 7 University, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fenaux", 
        "givenName": "Pierre", 
        "id": "sg:person.0766554473.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0766554473.71"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2018-06-06", 
    "datePublishedReg": "2018-06-06", 
    "description": "In 1993 Silverman and coworkers [1] reported on a phase 2 trial on 43 patients with higher-risk MDS (medullary blast count >10%) using 75\u00a0mg/m2 5-Azacytidine (5-Aza) for 7\u00a0days every 28\u00a0days for 6 cycles. Forty-nine percent of the patients responded, with 12% CR (CR and PR 37%, and 5% improved hematologically without achieving CR or PR), and 51% were nonresponders. This report was the first to show that 5-Aza can result in remission in a reasonable proportion of the patients, and results were very closely reproduced in phase 2 and 3 trials [2\u201318]. The drug was regarded as differentiating agent, and the authors speculated if 5-Aza was the first drug with benefit for older MDS patients. In 1997 Wijermans et al. [19] published promising phase 2 data on decitabine in high-risk MDS with similar results and subsequently worked on different schedules and on cytogenetic responses as well. Having in mind the very poor prognosis of older high-risk MDS patients after induction chemotherapy [20, 21], the efficacy of HMA appears to be an attractive alternative.", 
    "editor": [
      {
        "familyName": "Platzbecker", 
        "givenName": "Uwe", 
        "type": "Person"
      }, 
      {
        "familyName": "Fenaux", 
        "givenName": "Pierre", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-319-76879-3_10", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-319-76878-6", 
        "978-3-319-76879-3"
      ], 
      "name": "Myelodysplastic Syndromes", 
      "type": "Book"
    }, 
    "keywords": [
      "high-risk MDS", 
      "hypomethylating agent", 
      "MDS patients", 
      "promising phase 2 data", 
      "high-risk MDS patients", 
      "older MDS patients", 
      "phase 2 trial", 
      "phase 2 data", 
      "induction chemotherapy", 
      "cytogenetic response", 
      "poor prognosis", 
      "first drug", 
      "patients", 
      "different schedules", 
      "phase 2", 
      "trials", 
      "drugs", 
      "days", 
      "remission", 
      "similar results", 
      "nonresponders", 
      "chemotherapy", 
      "prognosis", 
      "agents", 
      "decitabine", 
      "efficacy", 
      "treatment", 
      "MD", 
      "report", 
      "percent", 
      "reasonable proportion", 
      "proportion", 
      "response", 
      "attractive alternative", 
      "schedule", 
      "benefits", 
      "m2", 
      "results", 
      "data", 
      "alternative", 
      "authors", 
      "cycle", 
      "coworkers", 
      "et al", 
      "mind", 
      "Cr", 
      "Silverman", 
      "al"
    ], 
    "name": "Treatment with Hypomethylating Agents (HMA)", 
    "pagination": "131-139", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1104407947"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-319-76879-3_10"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-319-76879-3_10", 
      "https://app.dimensions.ai/details/publication/pub.1104407947"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-08-04T17:16", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/chapter/chapter_238.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-319-76879-3_10"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-76879-3_10'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-76879-3_10'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-76879-3_10'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-319-76879-3_10'


 

This table displays all metadata directly associated to this object as RDF triples.

122 TRIPLES      22 PREDICATES      72 URIs      65 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-319-76879-3_10 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nf75afb04a1224145bbd7487d391d3e4d
4 schema:datePublished 2018-06-06
5 schema:datePublishedReg 2018-06-06
6 schema:description In 1993 Silverman and coworkers [1] reported on a phase 2 trial on 43 patients with higher-risk MDS (medullary blast count >10%) using 75 mg/m2 5-Azacytidine (5-Aza) for 7 days every 28 days for 6 cycles. Forty-nine percent of the patients responded, with 12% CR (CR and PR 37%, and 5% improved hematologically without achieving CR or PR), and 51% were nonresponders. This report was the first to show that 5-Aza can result in remission in a reasonable proportion of the patients, and results were very closely reproduced in phase 2 and 3 trials [2–18]. The drug was regarded as differentiating agent, and the authors speculated if 5-Aza was the first drug with benefit for older MDS patients. In 1997 Wijermans et al. [19] published promising phase 2 data on decitabine in high-risk MDS with similar results and subsequently worked on different schedules and on cytogenetic responses as well. Having in mind the very poor prognosis of older high-risk MDS patients after induction chemotherapy [20, 21], the efficacy of HMA appears to be an attractive alternative.
7 schema:editor N872ef1378f9a43d284094c6c97bd5260
8 schema:genre chapter
9 schema:isAccessibleForFree false
10 schema:isPartOf N131bbb3e570d48f7961c6944fc0429dd
11 schema:keywords Cr
12 MD
13 MDS patients
14 Silverman
15 agents
16 al
17 alternative
18 attractive alternative
19 authors
20 benefits
21 chemotherapy
22 coworkers
23 cycle
24 cytogenetic response
25 data
26 days
27 decitabine
28 different schedules
29 drugs
30 efficacy
31 et al
32 first drug
33 high-risk MDS
34 high-risk MDS patients
35 hypomethylating agent
36 induction chemotherapy
37 m2
38 mind
39 nonresponders
40 older MDS patients
41 patients
42 percent
43 phase 2
44 phase 2 data
45 phase 2 trial
46 poor prognosis
47 prognosis
48 promising phase 2 data
49 proportion
50 reasonable proportion
51 remission
52 report
53 response
54 results
55 schedule
56 similar results
57 treatment
58 trials
59 schema:name Treatment with Hypomethylating Agents (HMA)
60 schema:pagination 131-139
61 schema:productId N523b742873d343e5843dbac0d10af362
62 Nfd1de9ad8fe94fdcbb834731907a461b
63 schema:publisher N66c98351dea8496db7fd253e20dba125
64 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104407947
65 https://doi.org/10.1007/978-3-319-76879-3_10
66 schema:sdDatePublished 2022-08-04T17:16
67 schema:sdLicense https://scigraph.springernature.com/explorer/license/
68 schema:sdPublisher Nf7730c4de446414ca0f94aeb594cb1ab
69 schema:url https://doi.org/10.1007/978-3-319-76879-3_10
70 sgo:license sg:explorer/license/
71 sgo:sdDataset chapters
72 rdf:type schema:Chapter
73 N131bbb3e570d48f7961c6944fc0429dd schema:isbn 978-3-319-76878-6
74 978-3-319-76879-3
75 schema:name Myelodysplastic Syndromes
76 rdf:type schema:Book
77 N4279dc77d9e54abf8f44363af2e96db2 rdf:first sg:person.0766554473.71
78 rdf:rest rdf:nil
79 N523b742873d343e5843dbac0d10af362 schema:name dimensions_id
80 schema:value pub.1104407947
81 rdf:type schema:PropertyValue
82 N650af93729d0435883fc610c491a5926 schema:familyName Fenaux
83 schema:givenName Pierre
84 rdf:type schema:Person
85 N66c98351dea8496db7fd253e20dba125 schema:name Springer Nature
86 rdf:type schema:Organisation
87 N872ef1378f9a43d284094c6c97bd5260 rdf:first Nc43329fc6d324e3e82dfc8c114a56a91
88 rdf:rest N9ab096f8b637474d8839fd8ea2c219a7
89 N9ab096f8b637474d8839fd8ea2c219a7 rdf:first N650af93729d0435883fc610c491a5926
90 rdf:rest rdf:nil
91 Nc43329fc6d324e3e82dfc8c114a56a91 schema:familyName Platzbecker
92 schema:givenName Uwe
93 rdf:type schema:Person
94 Nf75afb04a1224145bbd7487d391d3e4d rdf:first sg:person.01362464041.20
95 rdf:rest N4279dc77d9e54abf8f44363af2e96db2
96 Nf7730c4de446414ca0f94aeb594cb1ab schema:name Springer Nature - SN SciGraph project
97 rdf:type schema:Organization
98 Nfd1de9ad8fe94fdcbb834731907a461b schema:name doi
99 schema:value 10.1007/978-3-319-76879-3_10
100 rdf:type schema:PropertyValue
101 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
102 schema:name Medical and Health Sciences
103 rdf:type schema:DefinedTerm
104 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
105 schema:name Oncology and Carcinogenesis
106 rdf:type schema:DefinedTerm
107 sg:person.01362464041.20 schema:affiliation grid-institutes:grid.411327.2
108 schema:familyName Germing
109 schema:givenName Ulrich
110 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20
111 rdf:type schema:Person
112 sg:person.0766554473.71 schema:affiliation grid-institutes:grid.413328.f
113 schema:familyName Fenaux
114 schema:givenName Pierre
115 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0766554473.71
116 rdf:type schema:Person
117 grid-institutes:grid.411327.2 schema:alternateName Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany
118 schema:name Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany
119 rdf:type schema:Organization
120 grid-institutes:grid.413328.f schema:alternateName Hôpital St Louis (Assistance Publique –Hôpitaux de Paris) and Paris 7 University, Paris, France
121 schema:name Hôpital St Louis (Assistance Publique –Hôpitaux de Paris) and Paris 7 University, Paris, France
122 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...